英派药业-B（IMPACT THERAP-B，股票代码：07630）近日宣布，已与Pharmanovia公司签署了一项独家许可协议。根据该协议，英派药业将其在研药物Senaparib的权益授予Pharmanovia，覆盖范围广泛，包括欧洲、中东、北非、澳大利亚以及新西兰等地区。这一战略合作不仅弥补了英派药业在相关区域的布局空白，也为其全球扩张注入了新动力。
英派药业-B（IMPACT THERAP-B，股票代码：07630）近日宣布，已与Pharmanovia公司签署了一项独家许可协议。根据该协议，英派药业将其在研药物Senaparib的权益授予Pharmanovia，覆盖范围广泛，包括欧洲、中东、北非、澳大利亚以及新西兰等地区。这一战略合作不仅弥补了英派药业在相关区域的布局空白，也为其全球扩张注入了新动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.